Editorial

The field of Pharmacology is thriving. As a science that draws on advances in many fields, Pharmacology, the discipline, and *Pharmacology*, the Journal, have both benefited from recent advances in genomics, molecular biology, novel animal models, combinatorial chemistry, high throughput screening, and insightful clinical studies. The importance of Pharmacology can also be seen in recent awards of Nobel prizes for studies of G-protein-receptor coupling, nitric oxide signaling, protein phosphorylation and molecular mechanisms of neurotransmission in the brain. Pharmacologic research is now poised to enter a new era by using molecular analysis of genotype to produce new and specific therapeutics, and to identify new drug targets in both mammals and pathogenic organisms.

I am honored to become the Editor for the US, Canada and South America. I am indebted to my predecessor, Dr. Elliot Vesell, for all of his guidance, support and direction. Dr. Vesell set a high standard as an Editor, and has left the Journal in excellent standing. I also express gratitude to Professors Donnerer and Watanabe for their continuing contributions. We will continue to focus on publication of high-quality, high impact studies. Rigorous peer-reviewed articles and critical reviews of specific areas will continue to be promoted. When appropriate, selected issues may be focused on a particular area, such as the October issue (61/3) devoted to Pharmacogenetics and Pharmacogenomics. In addition, we welcome critical and constructive input from our readers and contributors.

I look forward to the future with hope and enthusiasm.

Melvin L. Billingsley, PhD, Hershey, Pa.